Our Mission

At BreatheLabs, we’re developing intelligent lung health solutions that enable users to track their coughs with confidence, gain a better understanding of their lung health, and take steps to improve their overall respiratory wellbeing. 

One in ten people suffer from a persistent cough or a respiratory condition. By offering a comprehensive lung health solution, developed by lung health specialists, we’re empowering these individuals to live fuller, more active lives.

Our Founder

Adam Dessoky is the founder and CEO of BreatheLabs. A lifelong builder and investor, Adam’s journey into healthcare began after he observed close family members face a prolonged battle with chronic respiratory illness. Watching them navigate a system filled with gaps, outdated tools, and limited answers was both painful and motivating. Adam was struck by how little innovation and attention lung health receives, despite its profound impact on people’s lives. 

No stranger to using data and technology to solve overlooked, high-impact problems, Adam founded BreatheLabs in 2019 to close the lung health gap. Starting with the cough—an often ignored but powerful signal – BreatheLabs is developing smart solutions like the LungIQ™ cough tracker and BreatheLabsGummies to help people with chronic cough and other respiratory challenges better understand their health and take action to improve their wellbeing.

What started as a personal experience has grown into a mission to make lung health a reality for individuals with respiratory challenges.

Founder Adam Dessoky with his step brother, Oliver Watson who is a Paralympian Fencer and Asthma sufferer.

Our Medical Advisors

They’re distinguished leaders in their respective fields. They’re advocates for smart breathing solutions. Their insights are helping us take respiratory health to new heights. 

  • Dr. Wanda Phipatanakui
    Pediatric Health Expert

    St. Jean Emans Professor of Pediatrics at Harvard Medical School and Director of the Boston Children's Hospital Clinical Research Center, guides our pediatric research and data strategy. Advises on use cases related to asthma, allergy, and immunology.

  • Dr. Alyn Morice
    Chief Cough Officer

    Respiratory Medicine Professor & Academic Research Lead at Hull York Medical School and NHS Trust, a global expert in chronic cough and credited with helping define refractory cough as a distinct clinical entity. Advises on acoustic biomarkers and chronic cough phenotyping.

  • Dr. Bill Hanson
    Internist, Anesthesiologist, Intensivist

    Chief Medical Information Officer and Vice President of the University of Pennsylvania Health System, specializes as internist, anesthesiologist, and intensivist with deep expertise in medical informatics. Advises on clinical innovation at the intersection of respiratory care and emerging health technologies.

  • Dr. Charlie Strange
    Specialist in COPD and Rare Lung Diseases

    Professor of Pulmonary, Critical Care, Allergy and Sleep Medicine at the Medical University of South Carolina, leads research in COPD and rare lung diseases. Advises on use cases and innovation strategies related to COPD and rare pulmonary conditions.

  • Dr. Anne Vertigan
    Cough Behavioral Expert

    Associate Professor at the University of Newcastle and Manager of Speech Pathology at John Hunter Hospital in Australia. She published the first randomized controlled trial on speech therapy for chronic cough and led development of the internationally used Laryngeal Hypersensitivity Questionnaire. Advises on the potential benefits of behavior on lung health.

  • Alberto Paderno

    Dr. Alberto Paderno is a Head and Neck Surgeon and Assistant Professor of Otolaryngology at Humanitas University. He holds a PhD in Artificial Intelligence in Medicine and applies AI and computational imaging approaches to advance diagnostics. Advises on innovation at the intersection of medtech, clinical trials, and AI in healthcare.

Our Research

Developing Accurate Cough Detection Technology

Content Summary: This was our initial study demonstrating that BreatheLabs objectively counts coughs in real-world settings, with thorough benchmarking against manual counting methods.

Cough Detection in a Broad Population

Content Summary: This study extended the development of our initial algorithm, showing that BreatheLabs technology objectively measured cough in 247 individuals, including those with asthma, COPD, chronic cough of unknown origin, and those without diagnosed respiratory conditions.

Objective Cough Counting in the PACE Study

Content Summary: This study showed that BreatheLabs technology measured cough objectively over a 3+ week period in people with COPD.

Extending Cough Detection Algorithm for U.S.

Content Summary: This study adapted BreatheLabs technology for the U.S.-based population.

At Home Cough Monitoring During Behavioral Cough Therapy

Content Summary: This study, conducted in Australia, explored how BreatheLabs’ objective cough counting could support individuals undergoing behavioral interventions for chronic cough.

Extending Cough Detection Algorithm for India

Content Summary: This study adapted BreatheLabs technology for the population of India.

Full study details available upon request. Results may vary.

Full study details available upon request. Results may vary.

Your opportunity to create change

Breathe new life into your career. Be part of our mission driven team. 

LungIQ™ Cough Tracker

Gain a deeper understanding of your lung health
through objective cough tracking and real-life context.

Shop Now

How LungIQ™ Works

No patches or wearable devices. At home, in
the office, on vacation – LungIQ is designed to
be where you are.

How It Works